Brokerages expect Aetna Inc (NYSE:AET) to post $14.89 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for Aetna’s earnings. The highest sales estimate is $15.53 billion and the lowest is $14.30 billion. Aetna reported sales of $15.73 billion during the same quarter last year, which would suggest a negative year-over-year growth rate of 5.3%. The business is scheduled to issue its next quarterly earnings report on Tuesday, January 30th.

According to Zacks, analysts expect that Aetna will report full-year sales of $14.89 billion for the current financial year, with estimates ranging from $59.52 billion to $61.74 billion. For the next fiscal year, analysts expect that the business will post sales of $60.76 billion per share, with estimates ranging from $58.39 billion to $64.64 billion. Zacks’ sales calculations are an average based on a survey of research analysts that cover Aetna.

Aetna (NYSE:AET) last posted its quarterly earnings data on Tuesday, October 31st. The company reported $2.45 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.39. Aetna had a net margin of 2.93% and a return on equity of 21.84%. The firm had revenue of $14.99 billion during the quarter, compared to analysts’ expectations of $15.12 billion. During the same quarter in the previous year, the company posted $2.07 EPS. Aetna’s revenue was down 5.0% on a year-over-year basis.

Several research analysts recently weighed in on AET shares. Morgan Stanley boosted their price objective on shares of Aetna from $172.00 to $179.00 and gave the stock an “overweight” rating in a research report on Thursday, August 17th. Argus restated a “buy” rating and issued a $185.00 price objective (up previously from $165.00) on shares of Aetna in a research report on Tuesday, September 12th. Zacks Investment Research cut shares of Aetna from a “buy” rating to a “hold” rating in a research report on Tuesday, October 3rd. Jefferies Group upped their target price on shares of Aetna from $163.00 to $165.00 and gave the company a “hold” rating in a research report on Friday, October 13th. Finally, BMO Capital Markets assumed coverage on shares of Aetna in a research report on Monday, October 16th. They set a “market perform” rating and a $175.00 target price for the company. Twelve equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $175.19.

Aetna (AET) opened at $178.49 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.53 and a debt-to-equity ratio of 0.52. Aetna has a 1 year low of $116.04 and a 1 year high of $192.37. The firm has a market cap of $58,420.72, a P/E ratio of 17.54, a P/E/G ratio of 1.63 and a beta of 0.61.

The company also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Thursday, January 11th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.12%. The ex-dividend date is Wednesday, January 10th. Aetna’s dividend payout ratio (DPR) is 37.04%.

In other news, President Karen S. Lynch sold 15,271 shares of the business’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $161.91, for a total value of $2,472,527.61. Following the completion of the transaction, the president now owns 64,261 shares of the company’s stock, valued at approximately $10,404,498.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.90% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the company. FMR LLC boosted its stake in Aetna by 73.8% in the 2nd quarter. FMR LLC now owns 13,736,800 shares of the company’s stock worth $2,085,659,000 after purchasing an additional 5,833,567 shares during the period. Janus Henderson Group PLC boosted its stake in Aetna by 9,446.2% in the 2nd quarter. Janus Henderson Group PLC now owns 4,328,900 shares of the company’s stock worth $657,255,000 after purchasing an additional 4,283,553 shares during the period. Capital World Investors boosted its stake in Aetna by 8.9% in the 2nd quarter. Capital World Investors now owns 20,769,004 shares of the company’s stock worth $3,153,358,000 after purchasing an additional 1,688,767 shares during the period. Orbimed Advisors LLC boosted its stake in Aetna by 57.3% in the 3rd quarter. Orbimed Advisors LLC now owns 1,396,500 shares of the company’s stock worth $222,057,000 after purchasing an additional 508,600 shares during the period. Finally, Samlyn Capital LLC acquired a new position in Aetna in the 2nd quarter worth $77,170,000. 88.01% of the stock is owned by institutional investors.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at

About Aetna

Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.

Get a free copy of the Zacks research report on Aetna (AET)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Aetna (NYSE:AET)

Receive News & Ratings for Aetna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna and related companies with's FREE daily email newsletter.